Application of 19F magnetic resonance to study the efficacy of fluorine labeled drugs in the three-dimensional cultured breast cancer cells.
暂无分享,去创建一个
[1] Risto Penttinen,et al. Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy , 2009, Pharmacological Reviews.
[2] Sami Kilpinen,et al. Role of ErbB4 in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.
[3] A. Musolino,et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Purser,et al. Fluorine in medicinal chemistry. , 2008, Chemical Society reviews.
[5] David O'Hagan,et al. Understanding organofluorine chemistry. An introduction to the C-F bond. , 2008, Chemical Society reviews.
[6] Mangala Srinivas,et al. Fluorine‐19 MRI for visualization and quantification of cell migration in a diabetes model , 2007, Magnetic resonance in medicine.
[7] R. Mason,et al. 19F‐NMR detection of lacZ gene expression via the enzymic hydrolysis of 2‐fluoro‐4‐nitrophenyl β‐D‐galactopyranoside in vivo in PC3 prostate tumor xenografts in the mouse 1 , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] Xinrong Liu,et al. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[9] Y. Barenholz,et al. Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG‐independent, direct cytotoxic effects in cell cultures and in mice , 2006, The journal of gene medicine.
[10] E. D. de Vries,et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Larson,et al. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] Han van de Waterbeemd,et al. Pharmacokinetics and Metabolism in Drug Design: SMITH: PHARMACOKINETICS AND METABOLISM IN DRUG DESIGN O-BK , 2006 .
[13] J. Robertson,et al. Endocrine treatment options for advanced breast cancer--the role of fulvestrant. , 2005, European journal of cancer.
[14] Patrick J. Gaffney,et al. Quantitative “magnetic resonance immunohistochemistry” with ligand‐targeted 19F nanoparticles , 2004 .
[15] J. Bart,et al. Preclinical characterisation of 111In‐DTPA‐trastuzumab , 2004, British journal of pharmacology.
[16] Neal Rosen,et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors , 2004, Nature Biotechnology.
[17] G. Loo,et al. Disruption of mitochondria during tocotrienol-induced apoptosis in MDA-MB-231 human breast cancer cells. , 2004, Biochemical pharmacology.
[18] A. Abbott. Cell culture: Biology's new dimension , 2003, Nature.
[19] J. R. Reeves,et al. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.
[20] I. Zuhorn,et al. On the Mechanism of Cationic Amphiphile-mediated Transfection. To Fuse or not to Fuse: Is that the Question? , 2002, The Journal of Membrane Biology.
[21] M. Brechbiel,et al. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. , 2002, Nuclear medicine and biology.
[22] G. Hortobagyi,et al. Targeting HER2: recent developments and future directions for breast cancer patients. , 2001, Seminars in oncology.
[23] S. Kerwin,et al. Synthesis, DNA cleavage, and cytotoxicity of a series of bis(propargylic) sulfone crown ethers. , 2001, Bioorganic & medicinal chemistry.
[24] C. Moyes,et al. 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. , 2001, Journal of medicinal chemistry.
[25] D. Larsimont,et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. , 2000, American journal of clinical pathology.
[26] A. Sette,et al. Identification of HER2/neu‐derived peptide epitopes recognized by gastric cancer‐specific cytotoxic T lymphocytes , 1998, International journal of cancer.
[27] B. Dardzinski,et al. Rapid tissue oxygen tension mapping using 19F inversion‐recovery echo‐planar imaging of P erfluoro‐15 ‐crown‐5‐ether , 1994, Magnetic resonance in medicine.
[28] R. Kumar,et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. , 1994, The Journal of biological chemistry.
[29] P. Arenaz,et al. Genotoxic potential of crown ethers in mammalian cells: induction of sister-chromatid exchanges. , 1992, Mutation research.
[30] J. Montgomery,et al. Antibody-targeted liposomes: increase in specific toxicity of methotrexate-gamma-aspartate. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[31] G. Martin,et al. Extracellular matrix proteins give new life to cell culture , 1981, Hepatology.
[32] H. Kleinman,et al. Role of collagenous matrices in the adhesion and growth of cells , 1981, The Journal of cell biology.